EN DE
Watch Genexine Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Genexine Inc (095700) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of Genexine Inc stock KRW 1,699, price KRW 1,806, that is 6.0% below the price, quality 37 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7095700001

GI Genexine Inc logo Thin data Nov 16, 2026

Genexine Inc

095700 · KQ

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Ranks above peers (6/8) 
Fair value 1,699 KRW · Fairly valued 
Quality 37/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −24.4 %/yr in KRW) 
Negative free cash flow 
Narrow moat 12/100
Thin data 
Estimate
Watch Genexine Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

67,821 KRW 1,806 KRW Fair Value 1,699 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 1,806 KRW – 67,821 KRW · fair‑value band 1,274 KRW – 2,123 KRW · the 1,806 KRW price screens above the 1,699 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Genexine in your weekly email

Every Wednesday you see whether Genexine is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally.

Show moreShow less

The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells.

Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes.

The company is also developing GX-188E that is in Phase II clinical trials for the treatment of cervical cancer, and head and neck cancer. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013.

Genexine, Inc. was founded in 1999 and is headquartered in Seoul, South Korea.

Stock analysis

Genexine Inc (095700) currently trades at 1,806 KRW, while our estimate is 1,699 KRW, so the stock looks roughly fairly valued today (gap 6.4%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,274 KRW (bear) to 2,123 KRW (bull), the price of 1,806 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Genexine Inc reported revenue of 4.6B KRW in FY2025 versus 36.8B KRW in FY2021, a compound −40.6%/yr. Reported net income was −27.2B KRW in FY2025.

Key figures

Market cap 82.1B KRW (≈ $61.6M) Micro · P/S ratio 17.6 · EPS (TTM) −1,199 KRW · Return on equity −17.3% · Return on assets (EBIT) −8.7% (5-year average) · Operating margin −610% · Revenue (TTM) 5.8B KRW · Revenue growth (YoY) +200%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 75% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −6%, 095700 screens cheaper than that median.

Fair Value

Bear 1,274 KRW Fair Value 1,699 KRW Bull 2,123 KRW
Price 1,806 KRW · Downside -6.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 90
Are margins and returns getting better?
Cashflow 13
Do the profits arrive as real cash?
Financial strength 47
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 4
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+56.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.4%
Start year 2020 (pandemic). Over 10 years: −17.8% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−251.3% (2020) → −788.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 095700, get fair value alerts →

Compare Genexine Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 37 · Below median
Fair Value upside −6.0% · Above median
Profitability
Return on assets −7.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 199.6% · Top 25%
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.33× · Cheapest 25%
P/S (12 months) 14.14× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)25 · sector 2
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $957.76 $1,275 +33% vs 095700
Samsung Biologics Co 207940 1,366,000 KRW 1,552,100 KRW +14% vs 095700
Vertex Pharmaceuticals Incorporated VRTX $534.20 $587.62 +10% vs 095700
argenx SE ARGX $947.52 $908.40 −4% vs 095700
CSL Limited CSL A$199.38 A$186.49 −6% vs 095700
Moderna, Inc MRNA $206.80 $135.64 −34% vs 095700
BeOne Medicines AG 6160 HK$244.80 HK$152.92 −38% vs 095700
Revolution Medicines, Inc RVMD $162.69 $88.78 −45% vs 095700
Celltrion, Inc 068270 207,500 KRW 74,945 KRW −64% vs 095700
Royalty Pharma plc RPRX $68.68 $19.01 −72% vs 095700

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genexine Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Genexine Inc Fair Value". https://www.fairvalue-calculator.com/stock/095700

Frequently asked questions

Is Genexine Inc (095700) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 1,699 KRW versus a price of 1,806 KRW, about 6% lower (fairly valued).
What is the fair value of 095700?
Our estimate for Genexine Inc is 1,699 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 1,806 KRW.
What is the quality score of 095700?
Genexine Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genexine Inc (095700)?
Our calculated price target is the estimate of 1,699 KRW (as of Nov 16, 2026). Cautious scenario 1,274 KRW, optimistic scenario 2,123 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Genexine Inc stock forecast for 2026?
Our estimate puts fair value at 1,699 KRW, about 6% lower versus a price of 1,806 KRW (fairly valued). Cautious scenario 1,274 KRW, optimistic scenario 2,123 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Genexine Inc (095700)?
Genexine Inc reported trailing-twelve-month revenue of about 5.8B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Genexine Inc (095700)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genexine Inc it is 1,699 KRW per share (as of Nov 16, 2026), against a price of 1,806 KRW.
Is Genexine Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 095700 trades above its calculated fair value: price 1,806 KRW, fair value 1,699 KRW, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 095700?
No. The price is what the market pays today (1,806 KRW); the fair value is what the company's own numbers justify (1,699 KRW). For Genexine Inc the two are 107.46 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Genexine Inc worth?
The market values Genexine Inc at about 82.1B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 1,806 KRW; our models calculate a fair value of 1,699 KRW per share.
What do the bullish and bearish scenarios say about 095700?
Our models span a range for Genexine Inc: cautious scenario 1,274 KRW, base 1,699 KRW, optimistic 2,123 KRW per share (as of Nov 16, 2026, price 1,806 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genexine Inc (095700)?
Balance-sheet figures for Genexine Inc (as of Nov 16, 2026): return on equity −17.3%, debt of 0.03 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 095700 from its 52-week high?
Genexine Inc trades at 1,806 KRW, about 75% below its 52-week high of 7,100 KRW and at the low of 1,806 KRW (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of 1,699 KRW is for.
Which stocks are comparable to Genexine Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genexine Inc stock attractive at the current price?
The data as of Nov 16, 2026: price 1,806 KRW, calculated fair value 1,699 KRW (−6%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. Genexine Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genexine Inc (095700)?
The closing price on Nov 18, 2026 was 1,806 KRW. Our estimate is 1,699 KRW, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genexine Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Genexine Inc

How large is the market capitalisation of Genexine Inc (095700)?
The market capitalisation of Genexine Inc is 82.1B KRW (≈ $61.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genexine Inc (095700)?
The price-to-sales ratio of Genexine Inc is 17.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genexine Inc (095700)?
Earnings per share at Genexine Inc are −1,199 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Genexine Inc (095700)?
The return on equity (ROE) of Genexine Inc is −17.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genexine Inc (095700)?
On an EBIT basis the return on assets of Genexine Inc is −8.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genexine Inc (095700)?
The operating margin of Genexine Inc is −610% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genexine Inc (095700)?
Revenue at Genexine Inc is growing 200% versus a year earlier (3y avg −34.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Genexine Inc (095700) generate?
The free cash flow of Genexine Inc is −44.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Genexine Inc (095700) carry?
The net debt of Genexine Inc is 98.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Genexine Inc in the live analysis

One click puts Genexine Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.